[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"borderline-resectable-pancreatic-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:borderline-resectable-pancreatic-cancer":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,83,107,134,162],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100629649","phase-1-pdac-regression-and-intraoperative-surgical-margin-with-neoadjuvant-tamp-prism-tamp-100629649",false,"NCT07477418","PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)","PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP): A Phase Ib\u002FII Open-Label Trial","PRISM-TAMP","Inclusion Criteria:\n\n* Histologically confirmed pancreatic ductal adenocarcinoma (PDAC).\n* Borderline resectable disease as defined by the ABC classification criteria, incorporating one or more of the following:\n\n  * Anatomy (A): Vascular involvement consistent with borderline resectable or resectable locally advanced-PDAC (e.g., abutment of the superior mesenteric vein or artery, portal vein, or celiac axis) as determined by cross-sectional imaging\n  * Biology (B): Concern for extra-pancreatic metastasis or known N1 disease or suspicious but nonconfirmatory liver\u002Flung lesion(s). CA19-9\\>500 after normalized bilirubin\n  * Condition (C): Functional status and comorbidity profile adequate for curative-intent surgery, as assessed by the multidisciplinary team, specifically WHO PS \\>\u002F=1.\n* No prior treatment for PDAC (e.g., chemotherapy, radiation, or surgery).\n* Age ≥ 18 years.\n* ECOG performance status of 0 or 1.\n* Ability to understand and the willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n* Locally Advanced PDAC or metastatic PDAC\n* Histology other than adenocarcinoma\n* Non-accessible arterial anatomy\n* Gemcitabine hypersensitivity or contraindication to mFOLFIRINOX therapy based on provider assessment","ALL","18 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor survival outcomes, even when treated with modern chemotherapy and radiation. Patients with borderline resectable PDAC often receive neoadjuvant systemic therapy to improve the likelihood of successful surgical removal of the tumor, but rates of incomplete tumor regression and positive surgical margins remain high.\n\nThis Phase Ib\u002FII, single-arm study evaluates the safety and feasibility of adding trans-arterial microperfusion (TAMP) delivery of gemcitabine to standard neoadjuvant therapy for patients with borderline resectable PDAC. In this study, patients receive standard systemic chemotherapy with modified FOLFIRINOX followed by stereotactic body radiation therapy (SBRT). After completion of chemoradiation, gemcitabine is delivered directly to the tumor through the arterial blood supply using the RenovoCath® catheter system. Gemcitabine is an FDA-approved chemotherapy drug for pancreatic cancer, and the study is evaluating a novel method of delivering the drug rather than a new medication.\n\nThe primary objective of the study is to assess the safety and tolerability of neoadjuvant TAMP-delivered gemcitabine in this treatment setting. Secondary objectives include evaluation of surgical margin status and pathologic tumor regression following surgical resection. Exploratory analyses will examine relapse-free survival. Results from this study will help determine whether this locoregional chemotherapy approach can be safely integrated into neoadjuvant treatment strategies for patients with borderline resectable PDAC.",[28,29,30],"Pancreatic Ductal Adenocarcinoma (PDAC)","Borderline Resectable Pancreatic Cancer","Pancreatic Neoplasms",[32,33,34],"Neoadjuvant Therapy","Gemcitabine","Intra-arterial Chemotherapy","NOT_YET_RECRUITING","2026-03-12",{"date":38,"type":39},"2026-03-17","ACTUAL",{"date":41,"type":21},"2026-12",{"date":43,"type":21},"2031-12",{"name":45,"class":46},"University of Vermont","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":68,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":47},"100627418","eus-guided-ctcs--multi-omics-predicting-pancreatic-cancer-recurrence-and-metastases-100627418","NCT07448376","EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases","Exploratory Study on EUS-guided Portal Vein CTCs and Their Subtypes Combined With Multi-omics Detection for Early Warning of Pancreatic Cancer Recurrence and Metastasis","Inclusion Criteria:\n\n1. Patients with solid masses (diameter \\> 1 cm) in the pancreatic area within the accessible range of endoscopic ultrasound, as indicated by clinical symptoms, laboratory tests, and imaging examinations (MRI, CT, B-ultrasound), who require biopsy to clarify the nature of the lesion.\n2. Patients diagnosed with resectable pancreatic cancer, borderline resectable pancreatic cancer, locally advanced pancreatic cancer by imaging(CT\u002FMRI).\n3. Newly diagnosed pancreatic cancer patients who have not received radiotherapy or chemotherapy.\n4. Signed informed consent form.\n5. Patients must be able to comply with the trial requirements.\n\nExclusion Criteria:\n\n1. Patients with other active malignant tumors\n2. Patients with coagulation dysfunction (PLT 50,000\u002Fmm3, INR \\> 1.5; roughly estimated, INR \\> 1.5 is approximately equivalent to PT \\> 18 seconds)\n3. Pregnant women\n4. Patients with hemorrhagic diseases\n5. Patients with a history of taking anticoagulant drugs such as aspirin and warfarin in the past week\n6. Patients with absolute contraindications to EUS examination, a history of acute pancreatitis within the past 2 weeks, a history of gastric surgery, pregnancy, severe diseases, or a history of allergy to anesthetics\n7. Patients whose EUS examination was terminated early due to esophageal stenosis, obstruction, large space-occupying lesions, rapid changes in the patient's heart rate or respiratory rate, patient intolerance, or a large amount of food residue, etc.\n8. Patients with known hepatitis C virus infection\n9. Patients with known human immunodeficiency virus (HIV) infection\n10. Patients with imaging examinations, EUS results, etc., suggesting pancreatic cystic space-occupying lesions\n11. Patients who have received radiotherapy or chemotherapy\n12. Patients with incomplete pathological information, unable to make a clear diagnosis, or unable to sign the informed consent form","70 Years",{"count":57,"type":21},20,"2 Years","OBSERVATIONAL","The investigators conduct a single-center, prospective, observational study to explore the value of EUS-guided portal vein circulating tumor cells (PV-CTCs) and their subtypes combined with multi-omics tests in the early warning of recurrence and metastasis of resectable pancreatic cancer(RPC) and borderline resectable pancreatic cancer (BRPC).",[62,63,64,65,29,66,67],"CTCs","Pancreatic Cancer","Liver Metastases","Relapse","Resectable Pancreatic Cancers","EUS",[67,69,63,70,71,72,73],"CTC","metastases","relapse","BRPC","RPC","2026-02-25",{"date":76,"type":39},"2026-03-04",{"date":78,"type":21},"2026-03-01",{"date":80,"type":21},"2027-12-30",{"name":82,"class":46},"Huazhong University of Science and Technology",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100529402","dce-mri-guided-neoadjuvant-chemotherapy-for-borderline-resectable-pancreatic-cancer-100529402","NCT06173310","DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer","Inclusion Criteria:\n\n* Adult patients (age 19 years or older).\n* Patients with newly diagnosed and untreated borderline resectable pancreatic cancer.\n* Patients with signed informed consent.\n\nExclusion Criteria:\n\n* Any history of prior radiation or chemotherapy or surgical removal for pancreatic cancer.\n* Participants with safety contraindications to MRI examination (determined by standard clinical screening).\n* Participants who are pregnant, lactating or are planning to become pregnant during the study.\n* Participants who are planning to father a child during the study.","19 Years",{"count":91,"type":21},50,[93],"NA","The goal of this study is to test whether chemotherapy guided by a new imaging method named DCE-MRI can more effectively reduce a pancreatic tumor, enabling curable surgery, over the conventional method when a tumor is categorized as borderline resectable pancreatic cancer. UAB radiological research team has been studying a cutting-edge imaging technique named dynamic contrast-enhanced magnetic resonance imaging, or DCE-MRI, for over 10 years. This technique has been globally used to calculate the blood flow of various tissues, including tumors. Blood flow often serves as a critical indicator showing a disease status. For example, a pancreatic tumor typically has low blood flow, so it can be used as an indicator to identify the presence of a pancreatic tumor. In addition, an effective therapy can result in the increase of blood flow in a pancreatic tumor during the early period of treatment. Therefore, the investigators may be able to determine whether the undergoing therapy is effective or not by measuring the change of blood flow in the pancreatic tumor and deciding whether to continue the therapy or try a different one.",[96],"Borderline-resectable Pancreatic Cancer","RECRUITING",{"date":99,"type":39},"2026-02-27",{"date":101,"type":39},"2024-10-10",{"date":103,"type":21},"2029-03",{"name":105,"class":46},"Ohio State University",2,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":133},"100617945","chemotherapy-with-or-without-imd10-focused-ultrasound-in-the-treatment-of-borderline-resectable-or-locally-advanced-pancreatic-cancer-100617945","NCT07325214","Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer","A Randomized Pivotal Clinical Trial Evaluating Chemotherapy Regimen Consisting of Irinotecan Hydrochloride, Oxaliplatin, Fluorouracil (5-FU) and Leucovorin With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable Pancreatic Cancer or Locally Advanced Pancreatic Cancer","Inclusion Criteria:\n\n* An individual must meet all the following criteria:\n* 1\\. Willing and able to understand and sign an ICF and to comply with all aspects of the protocol\n* 2\\. Aged between 18 and 85 years, inclusive\n* 3\\. Histologically or cytologically, pathologically confirmed diagnosis of PDAC.\n* 4\\. Classification as BRPC or LAPC according to the NCCN Guidelines (The latest Edition) by radiologic test (CT or MRI), eligible for chemotherapy regimen within 4 weeks of the screening visit\n* 5\\. Must have at least 1 measurable lesion per RECIST 1.1 criteria at the screening visit.\n* 6\\. The ECOG performance status 0 or 1\n* 7\\. Trial participant having laboratory values defined as: Neutrophil count ≥ 1.5 x 10\\^9\u002FL, Platelet count ≥ 100 x 10\\^9\u002FL, AST and ALT ≤ 2.5 x ULN, - Serum creatinine ≤ 1.5 x ULN\n* 8\\. Life expectancy is more than 12 weeks\n* 9\\. A female is eligible to trial participate if not pregnant, not breast feeding and either a woman not of childbearing potential or, if a woman of childbearing potential agrees to use highly effective methods of contraception\\* from screening to EOS\n* 10\\. A male trial participant with female partner(s) of childbearing potential agrees to use highly effective methods of contraception from screening to EOS\n\nExclusion Criteria:\n\n* An individual who meets any of the following criteria will be excluded from participating in this clinical trial:\n* 1\\. The presence of a cystic lesion within tumor to be treated, or at the pancreas adjacent to the treated tumor.\n* 2\\. Extensive scars or surgical clips observed in the region through which the ultrasound beam will pass\n* 3\\. Targeted tumor(s) is not clearly visible with IMD10.\n* 4\\. Tumor is not treatable by the working range of IMD10\n* 5\\. Patient has difficulty in lying in supine position\n* 6\\. Known history of severe hypersensitivity to ultrasound gel or to chemotherapies (irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin) used in this clinical trial\n* 7\\. Known history of another anti-tumor therapy including chemotherapy, radiation, and\u002For surgery for pancreatic cancer\n* 8\\. A cardiovascular condition at the time of the screening visit that deems trial participation inappropriate due to one or more of the following: ① Class III or IV heart failure according to New York Heart Association (NYHA) classification, ② Acute coronary syndrome (unstable angina or myocardial infarction) within the last 24 weeks, ③ Uncontrolled heart arrhythmia, ④ Other clinically significant cardiovascular abnormalities as determined by the investigator\n* 9\\. Known history at the time of the screening visit that deems trial participation inappropriate due to one or more of the following: ① Other uncontrolled chronic infectious diseases, ② Active autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis, Crohn's disease, multiple sclerosis, ankylosing spondylitis, etc.), ③ Congenital or acquired immunodeficiency diseases, such as cellular immunodeficiency, hypogammaglobulinemia, and hypergammaglobulinemia., ④ Clinically significant mental illness\n* 10\\. Known history of malignancies other than pancreatic cancer within the last 2 years, except for adequately treated basal cell or squamous cell skin cancer or carcinoma in situ (e.g., breast, cervix)\n* 11\\. Known history of major surgery within 4 weeks of the cycle 1 day 1 (C1D1)\n* 12\\. Pregnant and breastfeeding women\n* 13\\. Trial participating in another drug\u002Fdevice clinical trial or have participated in another drug\u002Fdevice clinical trial within 4 weeks of C1D1\n* 14\\. Trial participation in the clinical trial is deemed inappropriate at the investigator's discretion, either for ethical reasons or due to potential impact on the clinical trial's outcome","85 Years",{"count":116,"type":21},136,[93],"The purpose of this Interventional clinical trial is to evaluate safety and efficacy of 'IMD10 (focused ultrasound)' in the treatment of borderline resectable pancreatic cancer or locally advanced pancreatic cancer.",[63,29,120],"Locally Advanced Pancreatic Cancer",[122],"Focused Ultrasound","2026-01-08",{"date":125,"type":39},"2026-01-12",{"date":127,"type":21},"2026-04",{"date":129,"type":21},"2029-08",{"name":131,"class":132},"IMGT Co., Ltd.","INDUSTRY",5,{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":144,"conditions":145,"keywords":148,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":133},"100588683","a-new-clinical-pathway-for-personalized-management-of-borderline-resectable-and-locally-advanced-pancreatic-cancer-100588683","NCT06944587","A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer","A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer - Norwegian Pancreatic Cancer Trial-3 (NORPACT 3)","NORPACT-3","Inclusion Criteria:\n\n* Borderline resectable or locally advanced adenocarcinoma of the pancreas (NCCN, version 2, 2021) (Appendix 3)\n* Nx, M0 (UICC 8th version, 2016)\n* Cytological or histological confirmation of adenocarcinoma\n* Age \\>18 year\n* Considered able to receive primary chemotherapy and possible surgery\n* Written informed consent\n\nExclusion Criteria:\n\n* Co-morbidity or performance status precluding primary chemotherapy\n* Co-morbidity or performance status precluding pancreatectomy\n* Female patients in child-bearing age not using adequate contraception, pregnant or lactating women\n* Mental or physical disorders that could interfere with treatment of with the provision of informed consent\n* Any reason why, in the opinion of the investigator, the patient should not participate",{"count":143,"type":21},400,"NORPACT-3 is a nationwide, Norwegian single arm prospective study that evaluates the resectability rates and survival in patients with borderline resectable and locally advanced pancreatic cancer who received primary chemotherapy. Eligible patients are treated with primary chemotherapy possibly followed by surgical exploration and resection. All Norwegian centres performing pancreatic surgery have agreed to collaborate in this trial. The assignment of the medical intervention is not at the discretion of the investigator, but follow the national Norwegian guidelines regarding diagnostic work up, oncological and surgical treatment and follow up. The primary aim is a national resection rate of 50% in BRPC and 15% in LAPC in patients initiating primary chemotherapy, with adequate overall survival and morbidity\u002Fmortality (after resection median overall survival of 24 months, 1 year survival 80%, and 5 year survival \\>20% + 90 day postoperative mortality ≤5%, 90-day postoperative major morbidity (Clavien Dindo grade 3) ≤40%).",[120,29,146,147],"Pancreatectomy","Chemotherapy Effect",[149,150,29,120,146,147,151,152],"Primary chemotherapy","Resection rate","FDG PET-CT","ctDNA","2025-04-17",{"date":155,"type":39},"2025-04-25",{"date":157,"type":39},"2024-12-03",{"date":159,"type":21},"2028-12-31",{"name":161,"class":46},"Oslo University Hospital",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":173,"briefSummary":174,"conditions":175,"keywords":176,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":47},"100545891","phase-2-irinotecan-liposome-ii-in-combination-with-5-fulv-and-oxaliplatin-in-perioperative-treatment-of-borderline-resectable-pancreatic-cancer-100545891","NCT06387810","Irinotecan Liposome II in Combination With 5-FU\u002FLV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer","Irinotecan Liposome II in Combination With 5-FU\u002FLV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer：A Prospective, Single-arm, Multicenter, Phase II Study","undetermined","Inclusion Criteria:\n\n* According to the NCCN Clinical Practice Guidelines for Pancreatic Cancer (2024.V1 edition), patients with critically resectable pancreatic cancer.\n* Have at least one measurable lesion as a target lesion (according to RECIST v1.1);\n* Have not received any anti-tumor therapy (including radiotherapy, ablation, chemotherapy, targeting, immunotherapy, etc.) or investigational drug therapy;\n* ECOG: 0 \\~ 1;\n* Expected survival ≥3 months;\n* Adequate organ and blood function\n\nExclusion Criteria:\n\n* Pancreatic cancer of non-pancreatic ductal origin includes patients with pancreatic neuroendocrine carcinoma, pancreatic acinar cell carcinoma, pancreatic blastoma, and solid pseudopapillary tumor\n* Severe gastrointestinal dysfunction\n* Severe infection occurred within 4 weeks prior to initiation of treatment (CTCAE \\> Grade 2)\n* Blood clotting is abnormal, has a tendency to bleed, or is receiving thrombolytic or anticoagulant therapy\n* Have clinical symptoms or diseases of heart that are not well controlled, such as: (1) NYHA grade 2 or above heart failure; (2) Unstable angina pectoris; (3) Myocardial infarction occurred within 6 months; (4) Patients with clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention\n* Known allergy to irinotecan liposome II, other liposome products, oxaliplatin, 5-FU, calcium leucovorin, and any component of the above products\n* Known peripheral neuropathy (CTCAE≥ Grade 3)\n* In the investigator's judgment, subjects had other factors that might have led to their being forced to terminate the study, such as non-adherence to the protocol, other serious medical conditions (including mental illness) requiring combined treatment, clinically significant abnormalities in laboratory test values, or family or social factors that might affect subjects' safety or the collection of trial data","110 Years",{"count":172,"type":21},45,[25],"This is a prospective, single-arm, phase II study to evaluate the efficacy and safety of irinotecan liposome II in combination with oxaliplatin and 5-FU\u002FLV in perioperative treatment of borderline resectable pancreatic cancer in 45 patients.",[29],[177],"perioperative treatment, irinotecan liposome II","2024-07-08",{"date":180,"type":39},"2024-07-10",{"date":182,"type":39},"2024-04-17",{"date":184,"type":21},"2026-06-30",{"name":186,"class":46},"Peking Union Medical College Hospital"]